Improved Screening, Risk Assessment Needed for Colorectal Cancer in Younger Adults

Share this content:
Colorectal cancer screening decisions and risk assessment for adults younger than 50 years should be improved.
Colorectal cancer screening decisions and risk assessment for adults younger than 50 years should be improved.

Colorectal cancer (CRC) screening decisions and risk assessment for adults younger than 50 years should be improved, according to a study published in Cancer.1

National guidelines recommend CRC screening to begin at age 50. However, the percentage of CRC cases in younger patients is increasing.

To examine differences regarding disease stage at diagnosis, therapy patterns, and disease-specific survival, investigators conducted a population-based, retrospective cohort study of the Surveillance, Epidemiology, and End Results registry for patients diagnosed with CRC from 1998 to 2011.

Results showed that of 258 024 patients with CRC, 15% (37 847 patients) were younger than age 50. Younger patients with distant metastasis were more likely to receive surgery for their primary tumor (adjusted probability: 72% vs 63%; P < .001). Radiotherapy was also more likely to be administered in the younger patient population (adjusted probability: 53% vs 48%; P < .001).

RELATED: FOLFOX for Colorectal Cancer Patients With Low Absolute Neutrophil Counts

Investigators also found that patients who received screening prior to 50 years of age had better overall disease-specific survival (HR, 0.77; P < .001) even though a larger percentage presented with advanced disease.

Reference

  1. Abdelsattar ZM, Wong SL, Regenbogen SE, et al. Colorectal cancer outcomes and treatment patters in patients too young for average-risk screening [published online ahead of print on January 25, 2016]. Cancer. doi: 10.1002/cncr.29716.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs